Bar-Lev SchleiderL, MechoulamR, LedermanV, et al.Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018; 49:37–43.
2.
BradfordAC, BradfordWD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Milwood). 2016; 35:1230–1236.
3.
PowellD, PaculaRL, JacobsonM. Do medical marijuana laws reduce addiction and deaths related to pain killers?. J Health Economics. 2018; 58:29–42.
4.
ReimanA, WeltyM, SolomonP. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017; 2:160–166.
5.
AbramsDI, CoueyP, ShadeSB, et al.Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90:844–851.
6.
LynchME, ClarkAJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage. 2003; 25:496–498.
7.
MechoulamR, HanušLO, PertweeR, et al.Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014; 15:757–764.
8.
PacherP, BátkaiS, KunosG. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58:389–462.
9.
PertweeRG, HowlettAC, AboodME, et al.International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev., 2010; 62:588–631.
10.
EnglundA, FreemanTP, MurrayRM, et al.Can we make cannabis safer?. Lancet Psychiatry. 2017; 4:643–648.
